Ultragenyx Pharmaceutical | RARE - Operating Profit

Stock Price
24.45
Daily Change
-0.24 -0.97%
Monthly
5.80%
Yearly
-46.11%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $-170.89M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Kyowa Hakko Kirin JPY 25.86B 13.04B Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025